Mineralocorticoid Receptor Antagonist in the Art of Managing HFpEF

Live webinar on Wednesday 14th May 2025
@07:00 am EDT / 12:00 pm BST / 13:00 CEST / 15:00 GST

RESERVE YOUR SPOT FOR FREE!

Webinar Overview:

Mineralocorticoid receptor antagonists (MRAs) have long been an integral part of the guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), demonstrating significant morbidity and mortality benefits. However, emerging evidence from recent large-scale clinical trials has expanded our understanding of their role in heart failure with mid-range ejection fraction (HFmEF) and preserved ejection fraction (HFpEF).

Non-steroidal MRAs, such as finerenone, have garnered particular attention due to their more selective mechanism of action, which may offer advantages over traditional steroidal MRAs like spironolactone and eplerenone. Data from pivotal trials, including FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF, have provided compelling evidence that MRAs contribute to significant reductions in the combined endpoints of cardiovascular death and heart failure hospitalizations in patients with HFmEF and HFpEF.

This webinar will provide a comprehensive overview of the evolving role of MRAs in HFmEF and HFpEF, highlighting:

• The pathophysiology of mineralocorticoid receptor activation and its contribution to inflammation, fibrosis, and volume overload in heart failure.
• Key clinical trials and meta-analyses that support the expanded use of MRAs beyond HFrEF.
• Practical considerations for selecting appropriate patients for MRA therapy, with a focus on safety, renal function, and hyperkalemia risk mitigation.
• Future directions in MRA research and its integration into evolving heart failure treatment guidelines.

Learning Objectives:

By the end of this webinar, participants will be able to:

✅Evaluate the pathophysiologic role of mineralocorticoid receptor activation in heart failure and its implications for HFmEF/HFpEF management.
✅Analyze the latest clinical evidence supporting the use of MRAs in HFmEF/HFpEF, including recent trial data and guideline recommendations.
✅Assess the safety profile of MRAs, including the risks of hyperkalemia, renal dysfunction, and other adverse effects in the HFmEF/HFpEF population.
✅Identify appropriate patients for MRA therapy, considering comorbid conditions, renal function, and serum potassium levels.
✅Develop individualized therapeutic plans incorporating MRAs into the broader management strategy for HFmEF/HFpEF, including combination therapy approaches and monitoring strategies.

Who should attend?

This session will be invaluable for cardiologists, primary care physicians, nurse practitioners, pharmacists, and other healthcare professionals involved in heart failure management.

♥ Meet Our International Expert Panel:

Dr Vebiona Kartini Prima Putri (Indonesia) – Moderator

Dr Craig Beavers (USA) – Speaker

Dr Bassam Atallah – Panelist

Dr Lorenz Van der Linden – Panelist

This educational activity, supported by an unrestricted educational grant from Bayer, is free of charge if watched live. On-demand recordings will be exclusive to ISCP members only. If you wish to join ISCP please visit our membership page for details on the options available: www.membership.iscpcardio.org